Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass A Randomized Controlled Trial
复制标题
DOI：
10.1097/aog.0b013e3181bdce0a
复制
发表时间：
2009-11-01
影响因子：
7.2
通讯作者：
Benhamou, Claude-Laurent
中科院分区：
文献类型：
--
作者：
McClung, Michael;Miller, Paul;Benhamou, Claude-Laurent
目的：评价唑来膦酸预防绝经后低骨量妇女骨丢失的疗效。在这项为期2年的随机、多中心、双盲、安慰剂对照研究中，随机选择低骨量绝经后妇女，在随机分组时和第12个月时静脉注射唑来膦酸5 mg（唑来膦酸2X 5 mg）、随机化时仅静脉注射唑来膦酸5 mg和第12个月时的安慰剂（唑来膦酸1X 5 mg）或随机化时和第12个月时的安慰剂（安慰剂）。结果：唑来膦酸2 × 5 mg和唑来膦酸1 × 5 mg治疗方案均显著增加了24个月时平均腰椎骨密度（BMD）（分别为5.18%和4.42%，与安慰剂相比为-1.32%，均P
OBJECTIVE: To evaluate the efficacy of zoledronic acid in the prevention of bone loss in postmenopausal women with low bone mass.METHODS: In this 2-year, randomized, multicenter, double-blind, placebo-controlled study, postmenopausal women with low bone mass were selected randomly to receive either zoledronic acid 5 mg intravenously at randomization and at month 12 (zoledronic acid 2X5 mg), zoledronic acid 5 mg intravenously only at randomization and placebo at month 12 (zoledronic acid 1X5 mg), or placebo at randomization and at month 12 (placebo). The primary efficacy endpoint was the percentage change in lumbar spine bone mineral density (BMD) (lumbar spine BMD) at month 24 relative to baseline.RESULTS: Both zoledronic acid 2X5 mg and zoledronic acid 1X5 mg regimens significantly increased mean lumbar spine BMD compared with placebo at month 24 (5.18% and 4.42% compared with -1.32%, respectively, both P